8th Neuropsychiatric Drug Development Summit

2025 continues to deliver progress, fueled by innovations in new mechanisms of action to improve neurotransmission, promote neuroplasticity, alleviate side effects, and more. However, as unmet needs rise and inherent challenges of heterogeneity, translatability, and placebo responses remain largely unresolved, the field is left to wonder: was Cobenfy just a ‘one-off’, or are we on the verge of a new wave of transformative approvals? Uniting 150+ discovery, preclinical, translational, clinical, and regulatory leaders, the 8th Neuropsychiatric Drug Development Summit returns to provide you with an unrivaled opportunity to stay attuned to the latest progress while tackling industry’s most pressing challenges across a wide spectrum of mental health indications. Recognized by key leaders as the "ideal size", offering a "targeted audience" perfect for meaningful networking and collaboration, join thought leaders from Bristol Myers Squibb, AbbVie, Otsuka, Johnson & Johnson, Biogen, Lundbeck, Delix Therapeutics, Boehringer Ingelheim and many more this September to revitalize the mental health drug development landscape.